肾康注射液联合达格列净与非奈利酮治疗气虚血瘀型糖尿病肾病患者的效果  

Effects of Shenkang injection combined with Dapagliflozin and Finerenone in treatment of diabetic nephropathy of qi deficiency and blood stasis type

作　　者：秦珍珍 徐在革 敖文[1] 吕朝阳[1] 李真真[1] QIN Zhenzhen;XU Zaige;AO Wen;LYU Chaoyang;LI Zhenzhen(Department of Endocrine Geriatrics of the 7th People’s Hospital of Zhengzhou,Zhengzhou 450000 Henan,China)

机构地区：[1]郑州市第七人民医院内分泌老年病科,河南郑州450000

出　　处：《中国民康医学》2025年第3期98-100,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察肾康注射液联合达格列净与非奈利酮治疗气虚血瘀型糖尿病肾病(DKD)患者的效果。方法:选取2022年3月至2024年3月该院收治的74例气虚血瘀型DKD患者进行前瞻性研究,按照随机数字表法将其分为对照组与观察组各37例。对照组采用达格列净与非奈利酮治疗,观察组在对照组基础上联合肾康注射液治疗。比较两组治疗前后血糖指标[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]、肾功能指标[尿素氮(BUN)、血肌酐(Scr)、肾小球滤过率(eGFR)]水平,以及治疗期间不良反应发生率。结果:治疗后,两组FPG、2hPG、HbA1c水平均低于治疗前,且观察组低于对照组,差异有统计学差异(P<0.05);治疗后,两组BUN、Scr水平均低于治疗前,且观察组低于对照组,两组e GFR水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为2.70%(1/37),低于对照组的24.32%(9/37),差异有统计学意义(P<0.05)。结论:肾康注射液联合达格列净与非奈利酮治疗气虚血瘀型DKD患者可降低血糖指标水平和不良反应发生率,改善肾功能指标水平,效果优于达格列净联合非奈利酮治疗。Objective:To observe effects of Shenkang injection combined with Dapagliflozin and Finerenone in treatment of diabetic nephropathy(DKD)patients of qi deficiency and blood stasis type.Methods:A prospective study was conducted on 74 DKD patients of qi deficiency and blood stasis type admitted to this hospital from March 2022 to March 2024.According to the random number table method,they were divided into control group and observation group,37 cases in each group.The control group was treated with Dapagliflozin and Finerenone,while the observation group was treated with Shenkang injection on the basis of those of the control group.The levels of blood glucose indexes[fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)]and renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr),glomerular filtration rate(eGFR)]before and after the treatment,and the incidence of adverse reactions during the treatment were compared between the two groups.Results:After the treatment,the levels of FPG,2hPG and HbA1c in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of BUN and Scr in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the eGFR levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the observation group was 2.70%(1/37),which was lower than 24.32%(9/37)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Shenkang injection combined with Dapagliflozin and Finerenone in the treatment of the DKD patients of qi deficiency and blood stasis type can reduce the levels of blood glucose indexes a

关 键 词：肾康注射液 达格列净 非奈利酮 糖尿病肾病 血糖 肾功能 不良反应 

分 类 号：R587.2[医药卫生—内分泌]